Table 1.
Baseline characteristics
|
Kamalapur |
Matlab |
All |
||||||
|---|---|---|---|---|---|---|---|---|
| LAIV (n=800) | Placebo (n=400) | LAIV (n=374) | Placebo (n=187) | LAIV (n=1174) | Placebo (n=587) | Total (n=1761) | ||
| Mean (range) age (months) | 42·7 (24–59) | 42·3 (24–59) | 42·2 (24–59) | 41·8 (24–59) | 42·5 (24–59) | 42·1 (24–59) | 42·4 (24–59) | |
| Age group (years) | ||||||||
| ≥2 to <3 | 248 (31·0%) | 138 (34·5%) | 105 (28·1%) | 53 (28·3%) | 353 (30·1%) | 191 (32·5%) | 544 (30·9%) | |
| ≥3 to <4 | 229 (28·6%) | 105 (26·3%) | 134 (35·8%) | 69 (36·9%) | 363 (30·9%) | 174 (29·6%) | 537 (30·5%) | |
| ≥4 to <5 | 323 (40·4%) | 157 (39·3%) | 135 (36·1%) | 65 (34·8%) | 458 (39·0%) | 222 (37·8%) | 680 (38·6%) | |
| Sex | ||||||||
| Male | 410 (51·3%) | 191 (47·8%) | 175 (4·8%) | 90 (48·1%) | 585 (49·8%) | 281 (47·9%) | 866 (49·2%) | |
| Female | 390 (48·8%) | 209 (52·3%) | 199 (53·2%) | 97 (51·9%) | 589 (50·2%) | 306 (52·1%) | 895 (50·8%) | |
| Underweight (weight for age malnutrition)* | ||||||||
| None | 203 (25·4%) | 103 (25·8%) | 106 (28·3%) | 48 (25·7%) | 309 (26·3%) | 151 (25·7%) | 460 (26·1%) | |
| Mild | 324 (40·5%) | 173 (43·3%) | 162 (43·3%) | 84 (44·9%) | 486 (41·4%) | 257 (43·8%) | 743 (42·2%) | |
| Moderate | 219 (27·4%) | 105 (26·3%) | 91 (24·3%) | 43 (23·0%) | 310 (26·4%) | 148 (25·2%) | 458 (26·0%) | |
| Severe | 54 (6·8%) | 19 (4·8%) | 15 (4·0%) | 12 (6·4%) | 69 (5·9%) | 31 (5·3%) | 100 (5·7%) | |
| Stunting (height for age malnutrition)* | ||||||||
| None | 152 (19·0%) | 84 (21·0%) | 111 (29·7%) | 47 (25·1%) | 263 (22·4%) | 131 (22·3%) | 394 (22·4%) | |
| Mild | 275 (34·4%) | 144 (36·0%) | 140 (37·4%) | 81 (43·3%) | 415 (35·3%) | 225 (38·3%) | 640 (36·3%) | |
| Moderate | 257 (32·1%) | 127 (31·8%) | 95 (25·4%) | 50 (26·7%) | 352 (30·0%) | 177 (30·2%) | 529 (30·0%) | |
| Severe | 116 (14·5%) | 45 (11·3%) | 28 (7·5%) | 9 (4·8%) | 144 (12·3%) | 54 (9·2%) | 198 (11·2%) | |
| Wasting (weight for height malnutrition)* | ||||||||
| None | 495 (61·9%) | 249 (62·3%) | 209 (55·9%) | 100 (53·5%) | 704 (60·0%) | 349 (59·5%) | 1053 (59·8%) | |
| Mild | 243 (30·4%) | 125 (31·3%) | 120 (32·1%) | 65 (34·8%) | 363 (30·9%) | 190 (32·4%) | 553 (31·4%) | |
| Moderate | 60 (7·5%) | 20 (5·0%) | 42 (11·2%) | 21 (11·2%) | 102 (8·7%) | 41 (7·0%) | 143 (8·1%) | |
| Severe | 2 (0·3%) | 6 (1·5%) | 3 (0·8%) | 1 (0·5%) | 5 (0·4%) | 7 (1·2%) | 12 (0·7%) | |
| Asthma or wheezing illness | ||||||||
| Previous hospital admission | 58 (7·3%) | 20 (5·0%) | 0 | 0 | 58 (4·9%) | 20 (3·4%) | 78 (4·4%) | |
| Previous treatment | 242 (30·3%) | 134 (33·5%) | 0 | 0 | 242 (30·3%) | 134 (33·5%) | 376 (21·4%) | |
LAIV=live attenuated influenza vaccine.
*
Z score, mild (−2 to <–1), moderate (−3 to <–2), or severe (<–3).